Acute Radiation Syndrome (ARS) is caused by exposure to a high dose of ionizing radiation over a short period of time, such as could occur after the meltdown of a nuclear reactor or the detonation of a “dirty bomb”. The acute signs and symptoms classically affect the hematologic, gastrointestinal, skin and central nervous systems.
The hematologic syndrome of ARS is characterized by severe decreases in the numbers of platelets and red and white blood cells due to the destruction of the bone marrow progenitor cells which produce these cells. Low numbers of these cells can result in uncontrollable bleeding, anemia, severe infection and death. PLX-R18 is being studied in collaboration with the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) as a treatment for the hematological syndrome of ARS.
U.S. National Institutes of Health to Support Development of Pluristem’s PLX-R18